The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Trial Profile

The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Velaglucerase alfa (Primary)
  • Indications Gaucher's disease type I; Gaucher's disease type III
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2018 Status changed from recruiting to withdrawn prior to enrolment.
    • 28 Feb 2018 Planned End Date changed from 1 Jul 2021 to 1 Oct 2017.
    • 28 Feb 2018 Planned primary completion date changed from 1 Jul 2021 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top